Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-carbamimidoyl-2-[2-hydroxy-5-(3-methoxyphenyl)-indan-1‑yl]-hexanoic acid is a synthetic small molecule belonging to the indane class of organic compounds. It has been studied as an experimental compound and is not approved for clinical use in any country. The compound features a unique indan-based structure with carbamimidoyl and methoxy substituents. Its mechanism of action and pharmacological targets are not described in public sources; it appears to be primarily used as a research ligand or chemical probe[1][3][9]. No clinical trials or approved indications are reported.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-carbamimidoyl-2-[2-hydroxy-5-(3-methoxyphenyl)-indan-1-yl]-hexanoic acid.